ESPR - Esperion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
49.66
-1.69 (-3.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close51.35
Open51.33
Bid48.70 x 900
Ask51.00 x 1000
Day's Range49.19 - 51.43
52 Week Range33.13 - 54.94
Volume327,806
Avg. Volume414,977
Market Cap1.4B
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-3.53
Earnings DateFeb 26, 2020 - Mar 2, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est80.92
  • Did Hedge Funds Drop The Ball On Esperion Therapeutics (ESPR) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Esperion Therapeutics (ESPR) ?

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

  • Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue?
    Zacks

    Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue?

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Esperion's Promising Drugs Under Review, Funds a Concern
    Zacks

    Esperion's Promising Drugs Under Review, Funds a Concern

    Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.

  • GlobeNewswire

    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Esperion (ESPR) today announced that, on November 20, 2019, the Compensation Committee of Esperion’s Board of Directors granted 61,705 restricted stock units (RSUs) to fifty-four new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest as to twenty-five percent of the shares on the one year anniversary of the recipient's start date, and will vest as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following the anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates.

  • Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%
    Zacks

    Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%

    Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

  • GlobeNewswire

    Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

    ANN ARBOR, Mich., Nov. 17, 2019 -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the.

  • GlobeNewswire

    Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results

    –  Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – –  Over 52-Weeks, Overall Adverse Events in the Bempedoic Acid Treatment.

  • President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR)
    Simply Wall St.

    President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR)

    Potential Esperion Therapeutics, Inc. (NASDAQ:ESPR) shareholders may wish to note that the President, Timothy...

  • Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned?
    Simply Wall St.

    Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned?

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...

  • Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3
    Zacks

    Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

    Esperion Therapeutics (ESPR) reports mixed third-quarter results.

  • GlobeNewswire

    Esperion to Participate in Upcoming Investor Conferences

    ANN ARBOR, Mich., Nov. 07, 2019 -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28th.

  • Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

    Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -25.37% and 5.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results

    ANN ARBOR, Mich., Nov. 06, 2019 -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended.

  • GlobeNewswire

    Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions

    ANN ARBOR, Mich., Nov. 04, 2019 -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the.

  • GlobeNewswire

    Esperion to Report Third Quarter 2019 Financial Results November 6, 2019

    ANN ARBOR, Mich., Oct. 29, 2019 -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets.

  • Should You Buy Esperion Therapeutics, Inc. (ESPR)?
    Insider Monkey

    Should You Buy Esperion Therapeutics, Inc. (ESPR)?

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]

  • GlobeNewswire

    Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List

    Esperion (ESPR) announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

  • Here's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • 7 Micro-Cap and Small-Cap Stocks That Insiders Are Buying
    InvestorPlace

    7 Micro-Cap and Small-Cap Stocks That Insiders Are Buying

    Insider buying could be a bullish signal for a stock. When an insider of a company wants to buy or sell their company's stock, they need to inform the U.S. Securities and Exchange Commission. An insider is a person who has access to confidential information about a company. In other words, the important people in a company need to tell the public if they are buying or selling their company's stock.I always like to know what the insiders are doing when I consider making an investment. Even more so, I like to see if they are buying after the price has dropped dramatically. A lack of insider buying could suggest that the selloff was justified, while meaningful buying could be a significant bullish signal. * 7 Stocks to Buy In a Flat Market There are many reasons why an insider of a company may decide to sell. They may need money tuition or to buy a new house. But there is only one reason why an insider would buy their company's stock. They believe it is undervalued and eventually they will make money.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThere has been significant buying by the insiders in the following micro-cap and small-cap stocks recently. Ideanomics (IDEX)Ideanomics Inc. (NASDAQ:IDEX) is a fintech company with significant operations in the Chinese electric vehicle market. It is currently trading with a valuation of around $200 million.Like many companies with exposure to China, IDEX has seen the price of its stock decline over the past year. However, it does seem to be coming back. Despite the recent volatility it is up 27% year-to-date. This company seems to have a lot going for it. Many analysts expect the Chinese EV market to expand rapidly over the next few year which would benefit IDEX.Additionally, in the most recent quarter the company reported earnings of 5 cents a share. This is a significant improvement over last year's loss of 12 cents in the same quarter. This could be a signal that Alfred Poor, who became the CEO a year ago, has begun to turn things around.Bruno Zheng Wu is the chairman of the company. He recently acquired a block of stock in a private transaction. The seller was having liquidity concerns due to issues with other investments, so Wu agreed to pay $3 a share for 1.7 million shares. This was a personal investment of over $5 million and could be a significant bullish signal. Briggs & Stratton (BGG)Briggs & Stratton (NYSE:BGG) designs, manufactures and sells gasoline engines and outdoor power equipment. After its recent price drop, the company has a market cap of $187 million. Most analysts would consider this to be a micro-cap stock.BGG stock dropped by almost 50% when it reported earnings which were way short of estimates. The company lost 45 cents a share while estimates called for a 45 cent profit. It traded at a multi-decade low but has since recovered a little.Some of the insiders must think that this selloff was an overreaction and that the stock is a good value at these levels. There has been significant insider buying. * 7 Deeply Discounted Energy Stocks to Buy Frank Jaehnert is a director of BGG. He just bought 40,000 shares at $4.39. This was a $175,600 investment. Vice President of Product Innovation Mike Zeiler just paid $4.25 for 43,000 shares. This was an investment of $180,000. Other insiders have recently purchased the stock as well. Esperion Therapeutics (ESPR)Esperion Therapeutics (NASDAQ:ESPR) operates as a clinical stage bio-pharmaceutical company. The current market cap is about $1 billion.ESPR stock has trended lower since June when it was trading around $52. Now it is around $35.This could be because the company continues to lose money. In early August it reported an earnings loss of $2.01 per share. Analysts were looking for a loss of around $1.85 per share.Tim Mayleben is the president and CEO of the company. He must think that the sellers have over-reacted to the news because he is buying the stock. He just made a substantial investment of $260,000 when he purchased 7,500 shares at an average price $34.55 on Sept. 6.Wall Street agrees with Mayleben that the stock is a good value at current levels. Twelve firms follow Esperion. Nine of them have "buy" ratings on it while there are two "holds" and one "sell." The average target price is around $85, significantly higher than current levels. Forterra (FRTA)Forterra (NASDAQ:FRTA) manufactures and sells pipe and precast products. At current levels the market valuation is around $402 million.FRTA stock has been on a roller coaster ride over the past year. After trading around $9 last August, it lost almost two-thirds of its value when it traded as low as $3.45 in December. Since then it has been very volatile, but it is slowly recovering and currently trading around $6 a share.Karl Watson is the CEO of Forterra. He is betting that this rally will continue. He just paid $5.98 for 20,000 shares. Back on Aug. 9, he made an even larger investment. He put $450,000 into the stock when he bought 65,200 shares at an average price of $6.94. * 7 Best Tech Stocks to Buy Right Now Other insiders have been buyers of the stock as well. Clinton McDonough is a director of Forterra. He recently bought 10,000 shares at $6.84. President of the Water & Pipes Products Divisions Vikrant Bhatia also made a substantial investment when bought 17,175 shares at $6.56 per share in August. Sally Beauty (SBH)Sally Beauty (NYSE:SBH) is an international retailer and distributor of professional beauty supplies. SBH stock's current market cap is around $1.6 billion.SBH has been trending lower since April. Now shares are in the $13 range. Some analysts believe that this is due to shareholders' concern about the trade war and predictions of a recession.This is in spite of the fact that it has solid earnings and at current levels has a very low forward price-to-earnings ratio of 6.John Miller is a director of the company. Apparently he thinks the stock will soon rally because he just made a $500,000 investment. He paid $12.21 for 40,500 shares. Marshall Eisenberg recently paid $11.89 for 10,000 shares. He is also a director of Sally Beauty. Harvest Capital Credit (HCAP)Harvest Capital Credit (NASDAQ:HCAP) is an externally managed closed-end investment company. This is a micro-cap company with a current market value of around $62 million.HCAP has been trending lower since reporting earnings and revenue that each fell short of expectations. Since then it has dropped by about 10%.CEO of Harvest Capital Credit Joe Jolson has made numerous investments in the stock. The most recently reported one was on Sept. 6. He made a $150,000 investment when he paid an average price of $9.77 for 15,100 shares. * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off In addition to this, over the prior few weeks he also bought about a total of 15,000 shares. It could be that he is attracted to the current dividend at these levels, which is almost 10%. Gulf Resources (GURE)Gulf Resources (NASDAQ:GURE) manufactures chemical products. At current levels it has a market valuation of about $34 million, making it a micro-cap company.Like many other companies in this sector, Gulf has been facing some challenges. This stock has lost about half of its value since April when it was trading around $1.41. The most recent close was 76 cents.As a penny stock company that is based in China, this company is probably an extremely risky investment. Remember, penny stocks are penny stocks for a reason.Ming Yang is a director of Gulf Resources. He must believe that despite the risk, it may be a good investment at current levels. He invested almost $500,000 into the stock when he bought over 660,000 shares at 72 cents.At the time of this writing, Mark Putrino did not have any positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 3 Artificial Intelligence Stocks to Buy * 7 Industrial Stocks to Buy for a Strong U.S. Economy * 3 Beaten-Down Bank Stocks to Buy and Hold for the Long Term The post 7 Micro-Cap and Small-Cap Stocks That Insiders Are Buying appeared first on InvestorPlace.

  • Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?
    Zacks

    Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?

    Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.com

    Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $259,125 of Shares

    President & CEO of Esperion Therapeutics Inc (30-Year Financial, Insider Trades) Timothy M Mayleben (insider trades) bought 7,500 shares of ESPR on 09/06/2019 at an average price of $34.55 a share. Continue reading...

  • Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
    Zacks

    Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study

    A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.

  • GlobeNewswire

    Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes

    — Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —— Provided 25% hsCRP Reduction —— No Worsening of Glycemic Control.

  • Esperion's Drugs in Review Hold Potential, Funds a Concern
    Zacks

    Esperion's Drugs in Review Hold Potential, Funds a Concern

    Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.